An interventional study of Citicoline and Docosahexaenoic Acid (DHA) in Glaucoma, sponsored by Institut Catala de Retina. Completed at 1 site in Spain. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-02.
Sponsored by Institut Catala de Retina · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Glaucoma with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Glaucoma · Spain.
Among the 43 studies in Glaucoma with a site in Spain, this one is the 21st largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2015, is one of 16 with no phase, and was the 36th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →7 of the 43 studies in Glaucoma with a site in Spain are open now. Recruiting first, the newest first:
Institut Catala de Retina · Sites in Spain
Ages 50–75
Clínica Rementería · Sites in Spain
Ages 18+
Fundacio Privada Mon Clinic Barcelona · Sites in Spain
Ages 18+
Hospital Clinic of Barcelona · Sites in Spain
Ages 40–80 · Healthy volunteers
Barbara Burgos Blasco · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 4 · Phase 4 8
First in 2003; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is above the median of 61 across 965 interventional studies indexed under Glaucoma.
Median enrollment 100 across the 33 interventional studies, 365 across the 10 observational. Of the 32 that completed or were terminated, 8 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 43 have an industry lead sponsor. The 10 most frequent:
Institut Catala de Retina is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Institut Catala de Retina has 3 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
1 of the studies in Glaucoma with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07322965Institut Catala de RetinaEvaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies in Glaucoma with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Pilot, single-blind, randomized and controlled study to evaluate the changes produced in the visual function of patients with glaucoma after oral administration for 3 months of citicoline and docosahexaenoic Acid (DHA) vs citicoline and docosahexaenoic Acid (DHA) vs vitamin C.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with chronic, primary or secondary, open or closed angle glaucoma, diagnosed by meeting the following criteria:
Glaucoma with functional and structural damage.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cebrolux 800 is a food supplement based on citicoline (163 mg) that also contains vitamin A, E, C and B6.
Dietary Supplement: Citicoline
Brudypio 1.5g is a food supplement based on Omega-3 fatty acid in the form of triglycerides (DHA 70% \[350 mg\], EPA 8.5%, DPA 6%) that also contains vitamins (A, B1, B2, B3, B6, B9, B12, C, E), carotenoids ( lutein, zeaxanthin, lycopene), glutathione, coenzyme Q10 and minerals (Zn, Se, Cu, Mn).
Dietary Supplement: Docosahexaenoic Acid (DHA)
Cebrolux 800 and Brudypio 1.5g (see above).
Dietary Supplement: Citicoline and Docosahexaenoic Acid (DHA)
Vitamin C.
Dietary Supplement: Vitamin C
Every subject randomized into this group have to take 2 sachets of Cebrolux 800 (362 mg of citicoline per day), every day, for 3 months.
Also known as: Cebrolux 800
Every subject randomized into this group have to take 3 pills of Brudypio 1.5g (1050 mg of DHA per day), every day, for 3 months.
Also known as: Brudypio 1.5g
Drug pages: Cytidine Diphosphate CholineStudies of Cytidine Diphosphate CholineCytidine Diphosphate Choline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Docosahexaenoic AcidsStudies of Docosahexaenoic AcidsDocosahexaenoic Acids pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Every subject randomized into this group have to take 2 sachets of Cebrolux 800 and 3 pills of Brudypio 1.5g per day, every day, for 3 months.
Every subject randomized into this group have to take 1 pills of Vitamin C (500 mg per day), every day, for 3 months.
Also known as: L-ascorbic acid
Effect on Mean Defect (MD)
Evaluation of changes on the MD (decibels) with study treatment.
Time frame: From Baseline to Month 3.
Effect on Visual Field Index (VFI)
Evaluation of changes on the VFI (%) with study treatment.
Time frame: From Baseline to Month 3.
Evaluation of the changes produced in the intraocular pressure (IOP)
To compare IOP (mmHg) measurements with study treatment.
Time frame: From Baseline to Month 3.
Evaluation of tolerance
Describe the tolerance and the adverse events with study treatment.
Time frame: From Month 1 to Month 3
Ran from Mar 2015 to primary completion in May 2022, 86 months.
Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's 86 months is above that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cytidine Diphosphate Choline · Docosahexaenoic Acids · Ascorbic Acid